Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MHLW 2009 Budget Requests ¥1.4 Billion To Strengthen PDMA Safety Measures

This article was originally published in PharmAsia News

Executive Summary

The Ministry of Health, Labor and Welfare released Aug. 26 a budget request for fiscal year 2009 of ¥22.85 trillion, an ¥829.2 billion and 3.8 percent increase compared to FY 2008's initial budget. The budget allocates ¥48.2 billion to stock up on flu drugs such as Tamiflu (oseltamivir)and Relenza (zanamavir) and pre-pandemic vaccines, and to develop pandemic vaccines. ¥33.2 billion is designated to develop new drugs in the areas of cancer, mental disorder, intractable and rare diseases and regenerative medicine. To boost safety measures in drugs and medical devices, ¥1.4 billion is allocated to the Pharmaceutical and Medical Device Agency to increase staff, and ¥900 million to the PDMA in establishing a consulting system to promote Japan-U.S.-Europe joint clinical trials and concurrent reviews for medical device. (Click here for more - Japanese language

Related Content

Japan’s MHLW Seeks 21% Budget Increase For Innovative Drugs



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts